Jyong Biotech shares surge 10.70% intraday amid FDA clarity potential for MCS-2 regulatory pathway.

Jyong Biotech surged 10.70% intraday amid developments surrounding a critical FDA regulatory review. The stock’s sharp intraday gain appears linked to market speculation or early signals regarding the agency’s assessment of the comparability of new API-2 batches to original API-1 batches for the urology candidate MCS-2. This regulatory milestone is essential for advancing the drug toward market approval, and positive developments—such as an implied or rumored green light—would strongly support the stock. While no direct confirmation was publicly issued, the timing of the price jump aligns closely with expectations that the FDA is nearing a decision on this key CMC issue, which has long been a bottleneck for the drug’s commercialization path.